



HHS Public Access

Author manuscript

Prog Neuropsychopharmacol Biol Psychiatry. Author manuscript; available in PMC 2020 March 08.

Published in final edited form as:

Prog Neuropsychopharmacol Biol Psychiatry. 2019 March 08; 89: 30–38. doi:10.1016/j.pnpbp.2018.08.021.

The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior

Jeffrey J. Moffat^{#b}, Eui-Man Jung^{#b}, Minhan Ka^c, Amanda L. Smith^b, Byeong Tak Jeon^a, Gijs W. E. Santen^d, and Woo-Yang Kim^{a,*}

^aDepartment of Biological Sciences, Kent State University, Kent, OH 44242, USA ^bUniversity of Nebraska Medical Center, Omaha, NE 68198, USA ^cResearch Center for Substance Abuse Pharmacology, Korea Institute of Toxicology, Daejeon, Republic of Korea ^dDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands

These authors contributed equally to this work.

Abstract

Haploinsufficiency of the chromatin remodeling factor *ARID1B* leads to autism spectrum disorder and intellectual disability. Several independent research groups, including our own, recently examined the effects of heterozygous deletion of *Arid1b* in mice and reported severe behavioral abnormalities reminiscent of autism spectrum disorders and intellectual disability as well as marked changes in gene expression and decreased body size. *Arid1b* heterozygous mice also display significant cortical excitatory/inhibitory imbalance due to altered GABAergic neuron numbers and impaired inhibitory synaptic transmission. Abnormal epigenetic modifications, including histone acetylation and methylation, are additionally associated with *Arid1b* haploinsufficiency in the brain. Treating adult *Arid1b* mutant mice with a positive GABA allosteric modulator, however, rescues multiple behavioral abnormalities, such as cognitive and social impairments, as well as elevated anxiety. While treating *Arid1b* haploinsufficient mice with recombinant mouse growth hormone successfully increases body size, it has no effect on aberrant behavior. Here we summarize the recent findings regarding the role of ARID1B in brain development and behavior and discuss the utility of the *Arid1b* heterozygous mouse model in neurodevelopmental and psychiatric research. We also discuss some of the opportunities and potential challenges in developing translational applications for humans and possible avenues for further research into the mechanisms of ARID1B pathology in the brain.

*Corresponding author: Woo-Yang Kim, Ph.D., wkim2@kent.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing interests
None

Keywords

ARID1B; autism; intellectual disability; neural progenitor; brain development; interneuron; GABA intervention

Introduction

ARID1B encodes AT-rich-interactive-domain-containing protein 1B (ARID1B), a subunit of the BAF chromatin remodeling complex. Haploinsufficiency of this gene has been linked to autism spectrum disorder (ASD) and intellectual disability (ID) (Hoyer et al., 2012; Santen et al., 2012; Tsurusaki et al., 2012; Santen et al., 2014). Recent studies from our group and others have now examined the effects of heterozygous deletion of *Arid1b* in mice, which provides multiple novel insights into the mechanisms and roles of *Arid1b* in the developing brain and in behavior and suggest potential pharmacologic treatments for *ARID1B*-related neurodevelopmental disorders (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). In this review we summarize and analyze these findings and provide potential plans for future research. Further understanding of ARID1B and its functions in the developing brain are now much more feasible with the availability and description of animal models and may play an important role in the future of neurodevelopmental and psychiatric disorder research.

ARID1B mutations in human patients

ARID1B mutations are prevalent in ID, a developmental disorder characterized by significant limitations in both intellectual function and adaptive behavior. An overall incidence is estimated to be between 1 and 8% (Roeleveld et al., 1997; Simonoff et al., 2006; Westerinen et al., 2007). As ID is a severely incapacitating condition that imposes a significant burden on affected individuals and their families, much work has been done to identify its underlying causes. ID has a genetic origin in the majority of cases, and studies of X-linked, autosomal-recessive, syndromic and sporadic cases have resulted in the identification of more than two thousand ID-associated genes. Mutational analysis in 887 patients with unexplained ID reveals nine different *de novo* nonsense or frameshift mutations predicted to cause *ARID1B* haploinsufficiency, indicating haploinsufficiency of ARID1B as a common cause of ID (Hoyer et al., 2012), which was also confirmed in more recent exome sequencing studies of large cohorts of ID patients, which identify ARID1B as the most frequent cause of ID (Wright et al., 2015).

Although ID is a very heterogeneous disease, it has long been recognized that there are syndromic subtypes of ID which are delineated by combinations of external features and/or congenital anomalies as syndromes. Coffin-Siris Syndrome (CSS) is such a syndrome, and aside from mild to severe ID, patients often have hypoplastic nails on the fifth finger and/or toe, coarse facial features, growth deficiencies, sparse scalp hair and hypertrichosis elsewhere (Schrier Vergano et al., 1993). Corpus callosum abnormalities are also often observed in individuals with CSS (Halgren et al., 2012; Santen et al., 2014; Mignot et al., 2016). To identify the genetic basis of CSS, Santen et al. utilize whole-exome sequencing on three diagnosed individuals, revealing *de novo* truncating mutations in one copy of *ARID1B* in all cases. Array-based copy-number variation analysis in 2,000 individuals diagnosed with

ID reveals 3 subjects with deletions in the *ARID1B* gene who also have phenotypes partially overlapping with that of CSS (Santen et al., 2012). Using exome sequencing in 23 individuals with CSS, another group shows 6 patients with *de novo* heterozygous mutations in the *ARID1B* gene, providing further evidence of *ARID1B* haploinsufficiency as a cause of CSS (Tsurusaki et al., 2012). In addition, several targeted sequencing studies confirm mutations in BAF complex genes in patients with CSS (Santen et al., 2013; Wieczorek et al., 2013; Tsurusaki et al., 2014).

ASD is characterized by significant communication and social interaction deficits as well as restricted interests and stereotyped behaviors (Walsh et al., 2011). ID is also a highly prevalent phenotype in individuals with ASD, seen in as many as 30-75% of those affected (Fombonne, 1999; O'Brien and Pearson, 2004; Perou et al., 2013; Baio et al., 2018). The SFARI Gene initiative, a comprehensive online database of genes and copy number variants associated with ASD, has identified *ARID1B* as one of the 25 high confidence genes related to autism. Indeed, many of the described *ARID1B* patients also have autism. Next generation sequencing and microarray analysis of samples from eight patients, all presenting with ID, shows *de novo* translocations or deletions resulting in a truncated copy of *ARID1B* in all cases (Halgren et al., 2012). Of these patients, 5 are diagnosed with ASD or have autistic traits. In addition, 4 of these 5 patients show corpus callosum abnormalities demonstrated by brain imaging. This finding suggests that structural defects may be associated with the cognitive and behavioral phenotypes stemming from *ARID1B* haploinsufficiency. A separate study shows that the transcript level of the *ARID1B* gene is reduced in individuals with ASD (Nord et al., 2011).

Taken together, these studies all emphasize the role *ARID1B* plays in proper brain development and behavior. Various *de novo* mutations resulting in haploinsufficiency cause ID, CSS, ASD, and corpus callosum abnormalities to varying degrees. These findings add to the growing evidence that mutations in chromatin-remodeling genes are important contributors to neurodevelopmental disorders (Ronan et al., 2013; Sokpor et al., 2017; Gabriele et al., 2018), and that several of these disorders with overlapping phenotypes have converging genetic causes.

***Arid1b* knockdown and neuronal development**

Proper neurite outgrowth and maintenance, which involve coordinated changes between the actin cytoskeleton and the microtubule network, are critical for normal neural development and brain function (Tsaneva-Atanasova et al., 2009). This process is regulated by the BAF (SWI/SNF) complex (Weinberg et al., 2013; Choi et al., 2015; Bachmann et al., 2016). *ARID1B* is a component of the mammalian BRG1/BRM associated factor (BAF) chromatin remodeling complex (Ho and Crabtree, 2010; Ronan et al., 2013) and plays an essential role in neurite outgrowth and maintenance. Using in utero shRNA delivery, Ka et al. show that *ARID1B* is required for dendrite outgrowth and arborization in cortical and hippocampal pyramidal neurons during brain development (Ka et al., 2016). In addition to decreased dendritic branching, *ARID1B*-deficient neurons exhibit markedly decreased dendritic innervation into cortical layer I and fewer attachments of dendritic terminals at the pial surface (Ka et al., 2016). It is noteworthy that layer I of the cerebral cortex receives inputs

primarily from neurons in higher-order thalamic and cortical areas, and neurons in this layer preferentially increase their activity during attention-demanding processes (Baluch and Itti, 2011; van Gaal and Lamme, 2012; Larkum, 2013). Thus, the decreased dendritic innervation into cortical layer I caused by ARID1B deficiency may disrupt balanced excitatory and inhibitory inputs and thereby give rise to pathologic conditions of ID and ASD.

Dendritic spines are the major sites of excitatory synaptic input in the brain and, therefore, form the basis of synaptic circuitry (Harris and Kater, 1994; Bourne and Harris, 2008). Ka et al. show that ARID1B contributes to spine formation, maturation and maintenance (Ka et al., 2016). ARID1B-deficient neurons exhibit a decreased number of dendritic spines and a prevalence of filopodia-like immature spines (Ka et al., 2016). The aberrant dendrites and spines in ARID1B-deficient pyramidal neurons greatly resemble the unbranched dendritic and filopodia-like spine morphology observed in mouse models of ID and ASD, as well as in Rett, Down, and fragile-X syndrome (FXS) models (Irwin et al., 2002; McKinney et al., 2005; Jentarra et al., 2010). Thus, ARID1B abnormalities may contribute to clinical outcomes by creating inappropriate synaptic connectivity. Incorrect growth and differentiation of dendrites is linked to the pathology of many neurodevelopmental and psychiatric diseases including ID, ASD and schizophrenia (Machado-Salas, 1984; Kaufmann and Moser, 2000; Fiala et al., 2002; Chapleau et al., 2009; Penzes et al., 2011). Abnormalities in the dendritic differentiation of cortical pyramidal neurons are seen in postmortem brain samples from individuals with ID (Huttenlocher, 1974). A reduction in spine size along dendrites is also reported in Down syndrome (Marin-Padilla, 1976; Roberts et al., 1996) and altered dendrite arborization in cortical pyramidal neurons is found in the brains of Rett syndrome patients (Belichenko et al., 1994; Armstrong, 2005).

Neural phenotypes of *Arid1b* knockout mice

Three recent independent studies, including our own, describe abnormal brain anatomy and cellular composition in *Arid1b* heterozygous mice (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). We observe normal density and distribution of pyramidal neurons, oligodendrocytes and astrocytes in *Arid1b* heterozygous mice in our study but find that GABAergic interneuron numbers are significantly reduced in *Arid1b* mutant mice, due to increased apoptosis and decreased proliferation of progenitors in the ganglionic eminence (Jung et al., 2017). The ventral ganglionic eminence is essential for the generation of GABAergic interneurons (Pleasure et al., 2000; Brandao and Romcy-Pereira, 2015). GABAergic interneurons containing parvalbumin (PV), calretinin, somatostatin or calbindin-D_{28k} are the primary source of GABA in the nervous system and play an important role in neural circuitry and activity (Kelsom and Lu, 2013; Butt et al., 2017). Specifically, the number of PV-positive interneurons is reduced in several brain regions including the cortex, amygdala, thalamus, and hippocampus in *Arid1b* heterozygous mice, but *Arid1b* haploinsufficiency does not lead to significant changes in the somatostatin-, calbindin- or calretinin-positive interneuron number in *Arid1b* heterozygous cortices (Jung et al., 2017). Decreases in GABAergic interneuron numbers in the cortex and hippocampus have previously been linked to autism and schizophrenia (Benes and Berretta, 2001; Pizzarelli and Cherubini, 2011) and, more specifically, the number of PV-positive interneurons has been shown to be significantly reduced in autism and schizophrenia in both mouse models

and postmortem brain tissue (Gogolla et al., 2009; Lawrence et al., 2010). Consistently, ASD-like behavioral profiles, such as social interaction and communication deficits with repetitive and stereotyped behavior, can be observed in PV knockout mice (Wohr et al., 2015). Neuronal excitatory/inhibitory balance is regulated at the synaptic level, and a reduction in inhibitory synapse number or strength results in a shift of that balance (Gao and Penzes, 2015; Nelson and Valakh, 2015). As a result, excitatory/inhibitory imbalance leads to broken synaptic homeostasis and facilitates the risk of the neurological disorders such as autism and schizophrenia. *Arid1b* heterozygous mice exhibit fewer inhibitory synaptic puncta, namely vesicular inhibitory amino acid transporter- (VGAT) and glutamic acid decarboxylase 2- (GAD2) positive puncta, in the cerebral cortex (Jung et al., 2017). In addition, glutamic acid decarboxylase 1 (*Gad1*) and *Gad2* expression levels are markedly decreased in *Arid1b* haploinsufficient mouse brains. Heterozygous deletion of *Arid1b* also leads to abnormal miniature inhibitory postsynaptic currents (mIPSC) frequencies, characterized by increased inter-event intervals and increased inhibitory synaptic cleft width (Jung et al., 2017). Furthermore, GABAergic interneuron neurite number and length are decreased in *Arid1b* heterozygous mice (Jung et al., 2017). Thus, *Arid1b* haploinsufficiency results in excitatory/inhibitory imbalance via decreased GABAergic interneuron numbers and impaired synaptic transmission of inhibitory signals.

Two other reports indicate that a small subset of *Arid1b* heterozygous mice are born with hydrocephalus (Celen et al., 2017; Shibutani et al., 2017), which corresponds well with some individuals with ASD (Turner et al., 2016) and a portion of patients with CSS who present with Dandy-Walker malformations (Schrier Vergano et al., 1993; Imai et al., 2001). Celen et al. also report reductions in the size of the cerebral cortex, corpus callosum and dentate gyrus, as well as decreased adult hippocampal neurogenesis, in *Arid1b* mutant mice (Celen et al., 2017). Shibutani et al. report no neuroanatomical abnormalities in non-hydrocephalic *Arid1b* haploinsufficient mice, but they also did not make any detailed histological examinations in that study (Shibutani et al., 2017). We also do not report any corpus callosum abnormalities, as we did not explicitly investigate the corpus callosum in the cited study (Jung et al., 2017).

Gene expression changes in *Arid1b* knockout mice

The ATP-dependent BAF chromatin remodeling complex regulates gene expression via nucleosome remodeling (Singhal et al., 2010; Alver et al., 2017). Considering ARID1B's role as a member of the BAF chromatin remodeling complex, it is unsurprising that heterozygous deletion of *Arid1b* leads to broad changes in gene expression in the brain. Shibutani et al. report that many of the genes shown to be up- and down-regulated in *Arid1b* heterozygous brains are similarly altered in human patients with ASD and in another animal model of autism (*Cdh8* heterozygous mice) (Shibutani et al., 2017). Celen et al. also report multiple changes in gene expression in *Arid1b* heterozygous mice, when compared to wild-type controls. In the adult hippocampus they find that genes associated with nervous system development and psychological, behavioral and developmental disorders appear to be distinctly affected. More specifically, they describe marked expression changes in Ephrin, nNOS, axonal guidance and glutamate receptor signaling pathway-related genes (Celen et al., 2017). Of the 140 differentially-expressed genes they identify, 91 are thought to be

directly targeted by the BAF chromatin remodeling complex (Attanasio et al., 2014; Celen et al., 2017) and 14 are included amongst the highest ranking autism risk genes in the SFARI database (Basu et al., 2009; Celen et al., 2017). A list of these genes can be found in Table 1.

Histone modifications such as acetylation and deacetylation are important for the regulation of gene expression (Eberharter and Becker, 2002; Kurdistani and Grunstein, 2003; Shahbazian and Grunstein, 2007; Bannister and Kouzarides, 2011; Lawrence et al., 2016). We report that *Arid1b* haploinsufficiency leads to an overall decrease in the acetylation of histone H3 at lysine 9 (H3K9ac) and tri-methylation of histone H3 at lysine 4 (H3K4me3), both markers of transcriptional activation, and an increase in tri-methylation of histone H3 at lysine 27, a marker for transcriptional repression (Figure 1) (Jung et al., 2017). We do not, however, report any global changes in histone acetyl-transferase (HAT) or histone deacetylase (HDAC) activity in *Arid1b* heterozygous brains, but do observe decreases in the level of acetyl-CREB-binding protein (CBP), which has been shown to enhance HAT function (Vecsey et al., 2007; Jung et al., 2017). In a similar vein, a previous study shows that HAT and HDAC activities are regulated by the interaction of ARID1B with HATs or HDACs in mouse osteoblast cells (Nagl et al., 2007). We also report decreased protein levels for PCAF, a HAT, in *Arid1b* homozygous embryonic brains, but not in *Arid1b* heterozygous brains, and decreased binding of several HATs to H3K9 acetylated sites in *Arid1b* heterozygous brains (Jung et al., 2017).

Corresponding with the overall reduction in PV-positive interneurons in *Arid1b* heterozygous cortices, we observe a decrease in *Pvalb* and *Ntrk2* transcripts in mutant brains. We further report that ARID1B binds to the *Pvalb* promoter in wild-type brains and that this localized binding is decreased in *Arid1b* heterozygous brains along with decreased H3K9ac in this region. One presumed effect of these changes is the decrease in transcriptional initiation for the *Pvalb* gene, shown by lower levels of the phosphorylated (ser5)-carboxy-terminal-domain of RNA polymerase II at the *Pvalb* promoter (Figure 1) (Jung et al., 2017). Therefore, ARID1B is likely an essential factor in regulating GABA neuron-associated genes through recruiting histone modification molecules to specific promoters and promoting chromatin remodeling for RNA polymerases to initiate gene transcription. These findings, in particular, provide insight into novel mechanisms for ARID1B-mediated gene regulation, as it appears that ARID1B-histone modifier interactions may act to facilitate gene transcription. It remains to be seen whether this is the case at the promoters of other genes altered in the *Arid1b* heterozygous mouse brain. These findings also suggest that the gross neural effects of *Arid1b*-deletion may be due to impaired stem cell differentiation via gene regulation during early development, as only a subset of inhibitory neurons are significantly decreased in *Arid1b* heterozygote mice.

Particularly, ARID1B may regulate histone modification at the Wnt signaling genes because *Arid1b* haploinsufficiency reduces the expression of Wnt- α -catenin signaling-related genes including *Cyclin D1*, *c-Myc*, *n-Myc*, *Creb*, *Lef1*, *Ctnnb1*, and others in inhibitory neural progenitors (Jung et al., 2017). A number of studies show that histone modifications can regulate cell proliferation and differentiation as well as cell death (Mehnert and Kelly, 2007; Roidl and Hacker, 2014; Li et al., 2018). Wnt signaling plays important roles in ventral progenitor proliferation during brain development (Liebner et al., 2008; Brandao and

Romcy-Pereira, 2015). Furthermore, expression of c-Myc, a key target of Wnt signaling and a cell cycle regulator, is decreased in ARID1B-deficient cells (Nagl et al., 2007). ARID1B deficiency also prevents the self-renewal capacity of embryonic stem cells (Yan et al., 2008). Thus, future studies should consider whether ARID1B can control Wnt- β -catenin signaling in ventral progenitor proliferation and development.

It should be noted that a number of studies have reported that the BAF complex and/or ARID1B repress Wnt- β -catenin signaling in vivo and in vitro in a subset of cell types (Vasileiou et al., 2015; Wu et al., 2016). A previous study, however, finds that BRG1, the central component of the BAF complex, physically interacts with β -catenin and facilitates target gene expression (Barker et al., 2001). Numerous studies demonstrate an extensive assortment of BAF complex configurations dependent on cell type and developmental stage (de la Serna et al., 2001; Olave et al., 2002; Lickert et al., 2004; Ohkawa et al., 2006; Cvekl and Duncan, 2007; Lessard et al., 2007; Li et al., 2013; Xiong et al., 2013; Son and Crabtree, 2014; Yu et al., 2015). This may explain the existence of apparently contradictory results regarding BAF complex regulation of Wnt- β -catenin. It is also possible that ARID1B's regulation of Wnt- β -catenin signaling in the developing brain occurs in a BAF-independent manner.

***Arid1b* haploinsufficiency and mouse behavior**

ASD is associated with a variety of mutated genes or copy-number variants. Because experimental mouse models are important for discovering the causes and pathogenesis of human disorders, there have been many attempts to develop genetic animal models of ASD based on human ASD-linked genetic mutations (Kazdoba et al., 2014). Typical hallmarks of ASD include impaired social behavior and communication, and repetitive and/or stereotyped behaviors. Additionally, ASD often presents with other co-occurring conditions, including depression, epilepsy, anxiety (Wing and Gould, 1979), attention deficit hyperactivity disorder (ADHD), ID, and motor coordination problems (Purpura et al., 2016). Similar behaviors are seen in animal models of ASD using specific tests developed to measure these behavioral abnormalities. One of the most commonly inherited genetic causes of ASD is FXS, which is caused by an expanded CGG repeat in the 5' untranslated portion of the fragile X mental retardation 1 gene (*FMR1*), leading to deficiency or absence of the FMR1 protein (Harris et al., 2008; Kogan et al., 2009). Mouse models of FXS (*Fmr1* knockout mice) exhibit several ASD- and ID-like behaviors such as anxiety, social behavior deficits, and cognitive deficiencies, although different groups report varying degrees of behavioral abnormalities and sometimes contradict one another (Harris and Kater, 1994; Peier et al., 2000; Yabe et al., 2004; McNaughton et al., 2008; Pietropaolo et al., 2011; Kazdoba et al., 2014). Due to the multiple variables present in mouse colony maintenance and in the inconsistent environmental conditions between laboratories, reproducing animal behavior, even in the same mouse model, is a difficult task. Without complete and detailed reporting of all protocols and experimental conditions, determining the grounds for discordant behavioral results is next to impossible. Contradictory results in the same mouse strains in different environments can be beneficial, however, as assays performed in standardized conditions actually have an increased likelihood of reporting false-positives (Richter et al., 2009). In

order to draw more accurate conclusions, it is therefore beneficial to compare behavioral experiment results between groups using the same or similar animal models.

Recently, three independent groups, including our own, developed mouse models of ARID1B haploinsufficiency. Two of the groups delete exon 5 of the *Arid1b* gene (Celen et al., 2017; Jung et al., 2017) while the other removes exon 3 (Shibutani et al., 2017), but both strategies appear to result in haploinsufficiency due to frameshift mutations. Celen et al. and Shibutani et al. generate the mutant mice using CRISPR/Cas9 gene editing while Jung et al. use a more traditional knockout strategy. The genetic background of the three mouse models is C57BL/6. Each group performed a different array of behavioral assays, many overlapping, and the results are generally concurrent, with a few exceptions. A summary of each group's results is described in Table 2. All three groups performed the elevated plus maze test for anxiety-like behavior. *Arid1b* heterozygous mice spend less time in the open arms of the maze and exhibit a lower percentage of entries into open arms, which indicates heightened anxiety (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). In the open field test, *Arid1b* heterozygous mice spend less time in the center area and enter the center area less frequently than controls, although their total travel distance is not different, which may also indicate anxiety-like behavior (Celen et al., 2017; Jung et al., 2017). In addition, *Arid1b* heterozygous mice avoid exploring the brightly-lit section in the light-dark box test, another common anxiety assay (Celen et al., 2017). *Arid1b* heterozygous mice also spend more time immobile in the forced swim and tail suspension tests, used to assess depression-like behavioral phenotypes (Jung et al., 2017), although Shibutani et al. report opposite results in the forced swim test (Shibutani et al., 2017).

As discussed above, one of the key characteristics of ASD is deficits in social behavior (Cohen et al., 1988). We use the three-chamber social assay to assess social interaction and social novelty preference. *Arid1b* heterozygous mice spend less time in the chamber containing an unfamiliar mouse than in the empty chamber, indicative of impaired social interaction, and also spend less time with a novel stranger mouse than they do with a more-familiar stranger (Jung et al., 2017). Celen et al. report that *Arid1b* heterozygous mice spend less time interacting with unfamiliar juvenile mice compared to WT littermates, when placed together in a fresh cage (Celen et al., 2017). We additionally report that *Arid1b* heterozygous mice spend less time interacting with one another when two unfamiliar mice of the same genotype are placed in the open field, compared with WT controls (Jung et al., 2017). Shibutani et al. evaluate social behavior between mice of the same genotype in a home-cage environment and observe decreased interaction between *Arid1b* heterozygous mice, compared with WT controls. In open field social interaction and three-chamber sociability and social novelty tests, however, Shibutani et al. do not report any differences between *Arid1b* heterozygous and control mice (Shibutani et al., 2017). This discrepancy could be due to a multitude of factors including animal stress, differences in protocols or environmental stimuli. Taken together, however, all three groups report significant impairments in social behavior in *Arid1b* heterozygous mice (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). These results agree with those seen in other mouse models of ASD, including haploinsufficiency of *Chd8* (Katayama et al., 2016).

Intellectual disability is a common comorbid disorder with ASD and is present in patients with haploinsufficient mutations of ARID1B (Santen et al., 2014), as well as in FXS (Harris et al., 2008). *Arid1b* heterozygous mice present with learning and memory deficits (Jung et al., 2017), which have also been observed in previous animal models of ASD (Kim et al., 2014). We use the Morris water maze test to assess cognitive function in *Arid1b* heterozygous mice. These mutant mice exhibit increased escape latencies during training trials and spend less time in the target quadrant during probe trials, with no changes in the distance or speed of swimming, compared with controls (Jung et al., 2017). However, another group reports that *Arid1b* heterozygous mice do not exhibit cognitive deficits as measured by the Morris water maze test (Celen et al., 2017). Celen and colleagues' results are unexpected and somewhat surprising given the strong neurogenetic evidence of *Arid1b* haploinsufficiency causing intellectual disability (Halgren et al., 2012; Hoyer et al., 2012; Santen et al., 2012). In the Barnes maze task, another assay of spatial learning and memory, Shibutani et al. report that *Arid1b* heterozygous mice demonstrate a similar latency to escape compared with wild type littermates, but, when the escape box is moved to the opposite side of the maze in a reversal task, mutant mice display a significantly longer latency to escape (Shibutani et al., 2017). This is indicative of increased perseveration or behavioral inflexibility. We also perform the novel-object recognition test to assess recognition memory. We find that *Arid1b* heterozygous mice demonstrate no preference for a novel object over a familiar one, whereas control mice spend considerably more time interacting with the novel object (Jung et al., 2017). *Arid1b* heterozygous mice are also less successful in the T-maze test, compared to controls (Jung et al., 2017). However, Shibutani et al. report that their *Arid1b* heterozygous mice do not demonstrate any deficiencies in the T-maze test, although they did not publish any of this data or report the method or protocol used (Shibutani et al., 2017). In addition, Celen et al. report that *Arid1b* heterozygous mice respond normally to foot shocks and perform similarly to controls in fear conditioning tests, while Shibutani et al. report that *Arid1b* heterozygous mice display a heightened response to foot shocks and enhanced performance in fear conditioning tests (Shibutani et al., 2017). Reports on FXS mouse models are also inconsistent in contextual and cued fear conditioning tests (Paradee et al., 1999; Dobkin et al., 2000; Van Dam et al., 2000; Auerbach et al., 2011; Ding et al., 2014; Kazdoba et al., 2014), which implies that these fear conditioning paradigms may be unreliable methods for testing cognitive deficits in genetic mouse models of ID.

In summary, *Arid1b* heterozygous mice demonstrate anxiety-like behavior, social behavior deficits and learning/memory impairments. Although there exists some contradiction regarding the results of a subset of individual behavioral assays, *Arid1b* heterozygous mice conveniently recapitulate many ASD-like and ID-like behavioral profiles, similar to those seen in other mouse models (Bilousova et al., 2009; Kazdoba et al., 2014; Katayama et al., 2016). Therefore, *Arid1b* heterozygous mouse models present a useful opportunity for advancing our understanding of the pathogenesis and underlying mechanisms of neurodevelopmental disorders and related behavioral defects.

GABA modulation as therapeutic interventions for *Arid1b* haploinsufficiency-induced neurodevelopmental conditions

As stark decreases in PV-positive interneurons are seen in *Arid1b* heterozygous cortices, in our study we attempt to rescue some of the behavioral deficits in these mice using a positive allosteric modulator for the GABA_A receptor, clonazepam (Jung et al., 2017). Clonazepam is shown to be effective in treating seizures and anxiety in humans (Dahlin et al., 2003) and also effectively ameliorates some of the behavioral deficits in the BTBR mouse ASD model (Han et al., 2014). Accordingly, we observe that a single intraperitoneal injection of clonazepam at a concentration of 0.0625 mg/kg for 0.5 to 1h prior to behavioral assays is sufficient to rescue impaired recognition memory, social memory and heightened anxiety-like behavior in adult *Arid1b* heterozygous mice but has no measurable effect on depression-like behaviors. Clonazepam treatment also rescues the decreased mIPSC frequency in *Arid1b* heterozygous mice (Jung et al., 2017). While it is encouraging to see that treatment with a GABA allosteric modulator is sufficient to rescue several of the hallmark behavioral abnormalities in this mouse model of ASD and ID, attempted restoration of the excitatory/inhibitory imbalance in *Arid1b* heterozygous mice does not lead to improvements in all behavioral tests. Thus, there appears to be more at play in this mouse model than a gross reduction in the interneuron population. Clonazepam, or related drugs, may still prove to alleviate some of the symptoms caused by excitatory/inhibitory imbalance, be it due to *ARID1B* haploinsufficiency or other causes. It is especially promising that this treatment leads to improved behavior in adult mice, which may indicate that treatment during a critical developmental window may not be entirely necessary to treat all consequences of *ARID1B* haploinsufficiency. A deeper understanding of the cell-types and circuits regulating the behaviors related to ASD and ID will be required to develop more targeted therapies.

Arid1b haploinsufficiency and body growth

All three groups find reduced body weight at multiple ages in *Arid1b* heterozygous mice, compared with controls (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). Jung et al. report that females show less obvious weight differences than males (Jung et al., 2017). Mice lacking one copy of *Arid1b* also develop disproportionately small kidneys and hearts (Celen et al., 2017). Celen et al. hypothesize that the growth hormone-releasing hormone–growth hormone–Insulin-like growth factor (GHRH-GH-IGF) axis deficiencies could be responsible for the smaller body size observed in *Arid1b* heterozygous mice and the short stature reported in *ARID1B* human patients (Santen et al., 2014; Celen et al., 2017). They report reduced IGF1 protein levels in the plasma and lower *Igf1* mRNA levels in the liver but no changes in GH in the pituitary gland or fasting plasma of *Arid1b* heterozygous mice. The pituitary gland also appears to respond normally to GHRH stimulation and they detect no change in *Ghrh* mRNA levels in the hypothalamus.

To ascertain whether this reduction in IGF1 in *Arid1b* heterozygous mice is indeed due to a problem with central nervous system (CNS) control of the GHRH-GH-IGF axis, Celen et al. conditionally delete one copy of *Arid1b* in the CNS and peripheral nervous system or in the liver by crossing *Arid1b*^{Fl/+} mice with *Nestin-Cre* mice or *Albumin-Cre* mice, respectively.

The *Nestin-Cre; Arid1b^{Fl/+}* mice present with a similar growth impairment and a reduction in plasma IGF1 levels with no accompanying increase in GH. *Albumin-Cre; Arid1b^{Fl/+}* mice do not demonstrate any significant differences in body size or in plasma IGF levels, when compared to controls. Therefore, nervous system-based haploinsufficiency of *Arid1b* is likely the cause of the growth retardation and GHRH-GH-IGF deficiencies observed in *Arid1b* heterozygous mice (Celen et al., 2017). It should be noted, however, that the *Nestin-Cre* mouse driver line has been reported to have hypopituitarism, decreased anxiety-like behavior and lower body weight (Galichet et al., 2010; Harno et al., 2013; Giusti et al., 2014; Declercq et al., 2015). As Celen et al. do not include the Cre-driver lines as controls in their conditional knockout experiments (Celen et al., 2017), these results should be cautiously interpreted until they can be independently confirmed. Celen et al. also attempt to treat the smaller body size and weight by correcting the apparent GHRH-GH-IGF deficiencies. They first treat *Arid1b* heterozygous mice with recombinant human IGF1, but this does not have any measurable effects on body weight or anxiety-like behavior. Treatment with recombinant mouse GH for 40 consecutive days, however, is sufficient to rescue the growth deficits and grip weakness in *Arid1b* haploinsufficient mice but has no measurable effect on anxiety-like behavior (Celen et al., 2017).

Concluding remarks/future directions

ARID1B research has made rapid advances in recent years, thanks in part to the development of *Arid1b* mutant mouse models. Because they closely recollect the behavioral effects of *ARID1B* mutations in the human population and resemble other ASD and ID mouse models, *Arid1b* mutant mice have the potential to provide profound insights into ARID1B's broad role in brain development and activity. *Arid1b* heterozygous mice may also continue to prove useful as preclinical models of excitatory/inhibitory imbalance in the brain.

Further research should continue to decipher the molecular mechanisms by which ARID1B regulates gene expression and, thus, brain function. Additionally, *Arid1b* heterozygous mice could be used to dissect neural circuits that regulate behaviors related to ASD and ID. Mouse models in which *Arid1b* can be conditionally deleted in specific neuronal subtypes will also provide more mechanistic insight, seeing as *Arid1b* homozygous mice do not survive postnatally (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). For example, we have already shown that hemizygous deletion of *Arid1b* in GABAergic interneurons recapitulates many of the behavioral abnormalities present in *Arid1b* heterozygous mice (Jung et al., 2017), but it may prove fruitful to further examine the effects of cell-type specific *Arid1b* deletion in other neuronal subsets. Drugs that influence histone modifiers may be another avenue worth exploring. Future studies are required to provide a better understanding of ARID1B's gene regulatory mechanisms. Overall, ARID1B is critical in regulating proper nervous system development and behavior. Recent advances in technology and the utilization and sharing of large data sets will help provide the tools necessary for major breakthroughs in neurodevelopmental disorder research around *ARID1B* haploinsufficiency.

Acknowledgments

Funding

This work was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS091220 to Woo-Yang Kim.

References

- Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, Haswell JR, Park PJ, Roberts CW (2017) The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. *Nat Commun* 8:14648. [PubMed: 28262751]
- Armstrong DD (2005) Neuropathology of Rett syndrome. *J Child Neurol* 20:747–753. [PubMed: 16225830]
- Attanasio C, Nord AS, Zhu Y, Blow MJ, Biddie SC, Mendenhall EM, Dixon J, Wright C, Hosseini R, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Afzal V, Ren B, Bernstein BE, Rubin EM, Visel A, Pennacchio LA (2014) Tissue-specific SMARCA4 binding at active and repressed regulatory elements during embryogenesis. *Genome Res* 24:920–929. [PubMed: 24752179]
- Auerbach BD, Osterweil EK, Bear MF (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. *Nature* 480:63–68. [PubMed: 22113615]
- Bachmann C, Nguyen H, Rosenbusch J, Pham L, Rabe T, Patwa M, Sokpor G, Seong RH, Ashery-Padan R, Mansouri A, Stoykova A, Staiger JF, Tuoc T (2016) mSWI/SNF (BAF) Complexes Are Indispensable for the Neurogenesis and Development of Embryonic Olfactory Epithelium. *PLoS Genet* 12:e1006274. [PubMed: 27611684]
- Baio J et al. (2018) Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. *MMWR Surveill Summ* 67:1–23.
- Baluch F, Itti L (2011) Mechanisms of top-down attention. *Trends Neurosci* 34:210–224. [PubMed: 21439656]
- Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. *Cell Res* 21:381–395. [PubMed: 21321607]
- Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H (2001) The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. *EMBO J* 20:4935–4943. [PubMed: 11532957]
- Basu SN, Kollu R, Banerjee-Basu S (2009) AutDB: a gene reference resource for autism research. *Nucleic Acids Res* 37:D832–836. [PubMed: 19015121]
- Belichenko PV, Oldfors A, Hagberg B, Dahlstrom A (1994) Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. *Neuroreport* 5:1509–1513. [PubMed: 7948850]
- Benes FM, Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. *Neuropsychopharmacology* 25:1–27. [PubMed: 11377916]
- Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J Med Genet* 46:94–102. [PubMed: 18835858]
- Bourne JN, Harris KM (2008) Balancing structure and function at hippocampal dendritic spines. *Annu Rev Neurosci* 31:47–67. [PubMed: 18284372]
- Brandao JA, Romcy-Pereira RN (2015) Interplay of environmental signals and progenitor diversity on fate specification of cortical GABAergic neurons. *Front Cell Neurosci* 9:149. [PubMed: 25972784]
- Butt SJ, Stacey JA, Teramoto Y, Vagnoni C (2017) A role for GABAergic interneuron diversity in circuit development and plasticity of the neonatal cerebral cortex. *Curr Opin Neurobiol* 43:149–155. [PubMed: 28399421]
- Celen C et al. (2017) Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. *Elife* 6.
- Chapleau CA, Larimore JL, Theibert A, Pozzo-Miller L (2009) Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in

neurodevelopmental disorders associated with mental retardation and autism. *J Neurodev Disord* 1:185–196. [PubMed: 19966931]

- Choi J, Jeon S, Choi S, Park K, Seong RH (2015) The SWI/SNF chromatin remodeling complex regulates germinal center formation by repressing Blimp-1 expression. *Proc Natl Acad Sci U S A* 112:E718–727. [PubMed: 25646472]
- Cohen IL, Fisch GS, Sudhalter V, Wolf-Schein EG, Hanson D, Hagerman R, Jenkins EC, Brown WT (1988) Social gaze, social avoidance, and repetitive behavior in fragile X males: a controlled study. *Am J Ment Retard* 92:436–446. [PubMed: 2965890]
- Cvekl A, Duncan MK (2007) Genetic and epigenetic mechanisms of gene regulation during lens development. *Prog Retin Eye Res* 26:555–597. [PubMed: 17905638]
- Dahlin MG, Amark PE, Nergardh AR (2003) Reduction of seizures with low-dose clonazepam in children with epilepsy. *Pediatr Neurol* 28:48–52. [PubMed: 12657420]
- de la Serna IL, Carlson KA, Imbalzano An (2001) Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation. *Nat Genet* 27:187–190. [PubMed: 11175787]
- Declercq J, Brouwers B, Pruniau VP, Stijnen P, de Faudeur G, Tuand K, Meulemans S, Serneels L, Schraenen A, Schuit F, Creemers JW (2015) Metabolic and Behavioural Phenotypes in Nestin-Cre Mice Are Caused by Hypothalamic Expression of Human Growth Hormone. *PLoS One* 10:e0135502. [PubMed: 26275221]
- Ding Q, Sethna F, Wang H (2014) Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. *Behav Brain Res* 271:72–78. [PubMed: 24886775]
- Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H, Brown WT (2000) Fmr1 knockout mouse has a distinctive strain-specific learning impairment. *Neuroscience* 100:423–429. [PubMed: 11008180]
- Eberharter A, Becker PB (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. *EMBO Rep* 3:224–229. [PubMed: 11882541]
- Fiala JC, Spacek J, Harris KM (2002) Dendritic spine pathology: cause or consequence of neurological disorders? *Brain Res Brain Res Rev* 39:29–54. [PubMed: 12086707]
- Fombonne E (1999) The epidemiology of autism: a review. *Psychol Med* 29:769–786. [PubMed: 10473304]
- Gabriele M, Lopez Tobon A, D'Agostino G, Testa G (2018) The chromatin basis of neurodevelopmental disorders: Rethinking dysfunction along the molecular and temporal axes. *Prog Neuropsychopharmacol Biol Psychiatry* 84:306–327. [PubMed: 29309830]
- Galichet C, Lovell-Badge R, Rizzoti K (2010) Nestin-Cre mice are affected by hypopituitarism, which is not due to significant activity of the transgene in the pituitary gland. *PLoS One* 5:e11443. [PubMed: 20625432]
- Gao R, Penzes P (2015) Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. *Curr Mol Med* 15:146–167. [PubMed: 25732149]
- Giusti SA, Vercelli CA, Vogl AM, Kolarz AW, Pino NS, Deussing JM, Refojo D (2014) Behavioral phenotyping of Nestin-Cre mice: implications for genetic mouse models of psychiatric disorders. *J Psychiatr Res* 55:87–95. [PubMed: 24768109]
- Gogolla N, Leblanc JJ, Quast KB, Sudhof TC, Fagiolini M, Hensch TK (2009) Common circuit defect of excitatory-inhibitory balance in mouse models of autism. *J Neurodev Disord* 1:172–181. [PubMed: 20664807]
- Halgren C et al. (2012) Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. *Clin Genet* 82:248–255. [PubMed: 21801163]
- Han S, Tai C, Jones CJ, Scheuer T, Catterall WA (2014) Enhancement of inhibitory neurotransmission by GABAA receptors having alpha2,3-subunits ameliorates behavioral deficits in a mouse model of autism. *Neuron* 81:1282–1289. [PubMed: 24656250]
- Harno E, Cottrell EC, White A (2013) Metabolic pitfalls of CNS Cre-based technology. *Cell Metab* 18:21–28. [PubMed: 23823475]
- Harris KM, Kater SB (1994) Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. *Annu Rev Neurosci* 17:341–371. [PubMed: 8210179]

- Harris SW, Hessler D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman RJ (2008) Autism profiles of males with fragile X syndrome. *Am J Ment Retard* 113:427–438. [PubMed: 19127654]
- Ho L, Crabtree GR (2010) Chromatin remodelling during development. *Nature* 463:474–484. [PubMed: 20110991]
- Hoyer J, Ekici AB, Ende S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, Zweier M, Gohring I, Zink AM, Rappold G, Schrock E, Wieczorek D, Riess O, Engels H, Rauch A, Reis A (2012) Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. *Am J Hum Genet* 90:565–572. [PubMed: 22405089]
- Huttenlocher PR (1974) Dendritic development in neocortex of children with mental defect and infantile spasms. *Neurology* 24:203–210. [PubMed: 4130661]
- Imai T, Hattori H, Miyazaki M, Higuchi Y, Adachi S, Nakahata T (2001) Dandy-Walker variant in Coffin-Siris syndrome. *Am J Med Genet* 100:152–155. [PubMed: 11298377]
- Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, Crisostomo RA, Larsen BP, Mehta A, Alcantara CJ, Patel B, Swain RA, Weiler IJ, Oostra BA, Greenough WT (2002) Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. *Am J Med Genet* 111:140–146. [PubMed: 12210340]
- Jentarra GM, Olfers SL, Rice SG, Srivastava N, Homanics GE, Blue M, Naidu S, Narayanan V (2010) Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation. *BMC Neurosci* 11:19. [PubMed: 20163734]
- Jung EM, Moffat JJ, Liu J, Dravid SM, Gurumurthy CB, Kim WY (2017) Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior. *Nat Neurosci* 20:1694–1707. [PubMed: 29184203]
- Ka M, Chopra DA, Dravid SM, Kim WY (2016) Essential Roles for ARID1B in Dendritic Arborization and Spine Morphology of Developing Pyramidal Neurons. *J Neurosci* 36:2723–2742. [PubMed: 26937011]
- Katayama Y, Nishiyama M, Shoji H, Ohkawa Y, Kawamura A, Sato T, Suyama M, Takumi T, Miyakawa T, Nakayama KI (2016) CHD8 haploinsufficiency results in autistic-like phenotypes in mice. *Nature* 537:675–679. [PubMed: 27602517]
- Kaufmann WE, Moser hW (2000) Dendritic anomalies in disorders associated with mental retardation. *Cereb Cortex* 10:981–991. [PubMed: 11007549]
- Kazdoba TM, Leach PT, Silverman JL, Crawley JN (2014) Modeling fragile X syndrome in the Fmr1 knockout mouse. *Intractable Rare Dis Res* 3:118–133. [PubMed: 25606362]
- Kelsom C, Lu W (2013) Development and specification of GABAergic cortical interneurons. *Cell Biosci* 3:19. [PubMed: 23618463]
- Kim SY, Burris J, Bassal F, Koldewyn K, Chattarji S, Tassone F, Hessler D, Rivera SM (2014) Fear-specific amygdala function in children and adolescents on the fragile X spectrum: a dosage response of the FMR1 gene. *Cereb Cortex* 24:600–613. [PubMed: 23146966]
- Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC (2009) Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. *Pediatrics* 124:1395–1403. [PubMed: 19805460]
- Kurdistani SK, Grunstein M (2003) Histone acetylation and deacetylation in yeast. *Nat Rev Mol Cell Biol* 4:276–284. [PubMed: 12671650]
- Larkum ME (2013) The yin and yang of cortical layer 1. *Nat Neurosci* 16:114–115. [PubMed: 23354381]
- Lawrence M, Daujat S, Schneider R (2016) Lateral Thinking: How Histone Modifications Regulate Gene Expression. *Trends Genet* 32:42–56. [PubMed: 26704082]
- Lawrence YA, Kempert TL, Bauman ML, Blatt GJ (2010) Parvalbumin-, calbindin-, and calretinin-immunoreactive hippocampal interneuron density in autism. *Acta Neurol Scand* 121:99–108. [PubMed: 19719810]
- Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R, Graef IA, Crabtree GR (2007) An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* 55:201–215. [PubMed: 17640523]

- Li F, Wan M, Zhang B, Peng Y, Zhou Y, Pi C, Xu X, Ye L, Zhou X, Zheng L (2018) Bivalent Histone Modifications and Development. *Curr Stem Cell Res Ther* 13:83–90. [PubMed: 28117006]
- Li W, Xiong Y, Shang C, Twu KY, Hang CT, Yang J, Han P, Lin CY, Lin CJ, Tsai FC, Stankunas K, Meyer T, Bernstein D, Pan M, Chang CP (2013) Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development. *Proc Natl Acad Sci U S A* 110:1738–1743. [PubMed: 23319608]
- Lickert H, Takeuchi JK, Von Both I, Walls JR, McAuliffe F, Adamson SL, Henkelman RM, Wrana JL, Rossant J, Bruneau BG (2004) Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. *Nature* 432:107–112. [PubMed: 15525990]
- Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czapalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signaling controls development of the blood-brain barrier. *J Cell Biol* 183:409–417. [PubMed: 18955553]
- Machado-Salas JP (1984) Abnormal dendritic patterns and aberrant spine development in Bourneville's disease--a Golgi survey. *Clin Neuropathol* 3:52–58. [PubMed: 6713754]
- Marin-Padilla M (1976) Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. *J Comp Neurol* 167:63–81. [PubMed: 131810]
- McKinney BC, Grossman AW, Elisseou NM, Greenough WT (2005) Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. *Am J Med Genet B Neuropsychiatr Genet* 136B:98–102. [PubMed: 15892134]
- McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ (2008) Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. *Behav Neurosci* 122:293–300. [PubMed: 18410169]
- Mehnert JM, Kelly WK (2007) Histone deacetylase inhibitors: biology and mechanism of action. *Cancer J* 13:23–29. [PubMed: 17464243]
- Mignot C et al. (2016) ARID1B mutations are the major genetic cause of corpus callosum anomalies in patients with intellectual disability. *Brain* 139:e64. [PubMed: 27474218]
- Nagl NG, Jr., Wang X, Patsialou A, Van Scoy M, Moran E (2007) Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. *EMBO J* 26:752–763. [PubMed: 17255939]
- Nelson SB, Valakh V (2015) Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. *Neuron* 87:684–698. [PubMed: 26291155]
- Nord AS, Roeb W, Dickel DE, Walsh T, Kusenda M, O'Connor KL, Malhotra D, McCarthy SE, Stray SM, Taylor SM, Sebat J, Network SP, King B, King MC, McClellan JM (2011) Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. *Eur J Hum Genet* 19:727–731. [PubMed: 21448237]
- O'Brien G, Pearson J (2004) Autism and learning disability. *Autism* 8:125–140. [PubMed: 15165430]
- Ohkawa Y, Marfella CG, Imbalzano AN (2006) Skeletal muscle specification by myogenin and Mef2D via the SWI/SNF ATPase Brg1. *EMBO J* 25:490–501. [PubMed: 16424906]
- Olave I, Wang W, Xue Y, Kuo A, Crabtree GR (2002) Identification of a polymorphic, neuron-specific chromatin remodeling complex. *Genes Dev* 16:2509–2517. [PubMed: 12368262]
- Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST (1999) Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. *Neuroscience* 94:185–192. [PubMed: 10613508]
- Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. *Hum Mol Genet* 9:1145–1159. [PubMed: 10767339]
- Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM (2011) Dendritic spine pathology in neuropsychiatric disorders. *Nat Neurosci* 14:285–293. [PubMed: 21346746]
- Perou R et al. (2013) Mental health surveillance among children--United States, 2005-2011. *MMWR Suppl* 62:1–35.
- Pietro Paolo S, Guillemot A, Martin B, D'Amato FR, Crusio WE (2011) Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. *PLoS One* 6:e17073. [PubMed: 21364941]

- Pizzarelli R, Cherubini E (2011) Alterations of GABAergic signaling in autism spectrum disorders. *Neural Plast* 2011:297153. [PubMed: 21766041]
- Pleasure SJ, Anderson S, Hevner R, Bagri A, Marin O, Lowenstein DH, Rubenstein JL (2000) Cell migration from the ganglionic eminences is required for the development of hippocampal GABAergic interneurons. *Neuron* 28:727–740. [PubMed: 11163262]
- Purpura G, Fulceri F, Puglisi V, Masoni P, Contaldo A (2016) Motor coordination impairment in children with autism spectrum disorder: a pilot study using Movement Assessment Battery for Children-2 Checklist. *Minerva Pediatr.*
- Richter SH, Garner JP, Wurbel H (2009) Environmental standardization: cure or cause of poor reproducibility in animal experiments? *Nat Methods* 6:257–261. [PubMed: 19333241]
- Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F (1996) The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. *Schizophr Res* 20:171–174. [PubMed: 8794506]
- Roeleveld N, Zielhuis GA, Gabreels F (1997) The prevalence of mental retardation: a critical review of recent literature. *Dev Med Child Neurol* 39:125–132. [PubMed: 9062428]
- Roidl D, Hacker C (2014) Histone methylation during neural development. *Cell Tissue Res* 356:539–552. [PubMed: 24817100]
- Ronan JL, Wu W, Crabtree GR (2013) From neural development to cognition: unexpected roles for chromatin. *Nat Rev Genet* 14:347–359. [PubMed: 23568486]
- Santen GW, Clayton-Smith J, consortium ABC (2014) The ARID1B phenotype: what we have learned so far. *Am J Med Genet C Semin Med Genet* 166C:276–289. [PubMed: 25169814]
- Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CA, van Ommen GJ, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M (2012) Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat Genet* 44:379–380. [PubMed: 22426309]
- Santen GW et al. (2013) Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. *Hum Mutat* 34:1519–1528. [PubMed: 23929686]
- Schrier Vergano S, Santen G, Wiczorek D, Wollnik B, Matsumoto N, Deardorff MA (1993) Coffin-Siris Syndrome In: *GeneReviews*((R)) (Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds). Seattle (WA).
- Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* 76:75–100. [PubMed: 17362198]
- Shibutani M, Horii T, Shoji H, Morita S, Kimura M, Terawaki N, Miyakawa T, Hatada I (2017) Arid1b Haploinsufficiency Causes Abnormal Brain Gene Expression and Autism-Related Behaviors in Mice. *Int J Mol Sci* 18.
- Simonoff E, Pickles A, Chadwick O, Gringras P, Wood N, Higgins S, Maney JA, Karia N, Iqbal H, Moore A (2006) The Croydon Assessment of Learning Study: prevalence and educational identification of mild mental retardation. *J Child Psychol Psychiatry* 47:828–839. [PubMed: 16898997]
- Singhal N, Graumann J, Wu G, Arauzo-Bravo MJ, Han DW, Greber B, Gentile L, Mann M, Scholer HR (2010) Chromatin-Remodeling Components of the BAF Complex Facilitate Reprogramming. *Cell* 141:943–955. [PubMed: 20550931]
- Sokpor G, Xie Y, Rosenbusch J, Tuoc T (2017) Chromatin Remodeling BAF (SWI/SNF) Complexes in Neural Development and Disorders. *Front Mol Neurosci* 10:243. [PubMed: 28824374]
- Son EY, Crabtree GR (2014) The role of BAF (mSWI/SNF) complexes in mammalian neural development. *Am J Med Genet C Semin Med Genet* 166C:333–349. [PubMed: 25195934]
- Tsaneva-Atanasova K, Burgo A, Galli T, Holcman D (2009) Quantifying neurite growth mediated by interactions among secretory vesicles, microtubules, and actin networks. *Biophys J* 96:840–857. [PubMed: 19186125]
- Tsurusaki Y, Okamoto N, Ohashi H, Mizuno S, Matsumoto N, Makita Y, Fukuda M, Isidor B, Perrier J, Aggarwal S, Dalal AB, Al-Kindy A, Liebelt J, Mowat D, Nakashima M, Saito H, Miyake N, Matsumoto N (2014) Coffin-Siris syndrome is a SWI/SNF complex disorder. *Clin Genet* 85:548–554. [PubMed: 23815551]

- Tsurusaki Y et al. (2012) Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat Genet* 44:376–378. [PubMed: 22426308]
- Turner AH, Greenspan KS, van Erp TGM (2016) Pallidum and lateral ventricle volume enlargement in autism spectrum disorder. *Psychiatry Res Neuroimaging* 252:40–45. [PubMed: 27179315]
- Van Dam D, D'Hooge R, Hauben E, Reyniers E, Gantois I, Bakker CE, Oostra BA, Kooy RF, De Deyn PP (2000) Spatial learning, contextual fear conditioning and conditioned emotional response in *Fmr1* knockout mice. *Behav Brain Res* 117:127–136. [PubMed: 11099766]
- van Gaal S, Lamme VA (2012) Unconscious high-level information processing: implication for neurobiological theories of consciousness. *Neuroscientist* 18:287–301. [PubMed: 21628675]
- Vasileiou G, Ekici AB, Uebe S, Zweier C, Hoyer J, Engels H, Behrens J, Reis A, Hadjihannas MV (2015) Chromatin-Remodeling-Factor ARID1B Represses Wnt/beta-Catenin Signaling. *Am J Hum Genet* 97:445–456. [PubMed: 26340334]
- Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough CB, Brindle PK, Abel T, Wood MA (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. *J Neurosci* 27:6128–6140. [PubMed: 17553985]
- Walsh P, Elsabbagh M, Bolton P, Singh I (2011) In search of biomarkers for autism: scientific, social and ethical challenges. *Nat Rev Neurosci* 12:603–612. [PubMed: 21931335]
- Weinberg P, Flames N, Sawa H, Garriga G, Hobert O (2013) The SWI/SNF chromatin remodeling complex selectively affects multiple aspects of serotonergic neuron differentiation. *Genetics* 194:189–198. [PubMed: 23457234]
- Westerinen H, Kaski M, Virta L, Almqvist F, Iivanainen M (2007) Prevalence of intellectual disability: a comprehensive study based on national registers. *J Intellect Disabil Res* 51:715–725. [PubMed: 17845240]
- Wieczorek D et al. (2013) A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. *Hum Mol Genet* 22:5121–5135. [PubMed: 23906836]
- Wing L, Gould J (1979) Severe impairments of social interaction and associated abnormalities in children: epidemiology and classification. *Journal of autism and developmental disorders* 9:11–29. [PubMed: 155684]
- Wohr M, Orduz D, Gregory P, Moreno H, Khan U, Vorckel KJ, Wolfer DP, Welzl H, Gall D, Schiffmann SN, Schwaller B (2015) Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. *Transl Psychiatry* 5:e525. [PubMed: 25756808]
- Wright CF et al. (2015) Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet* 385:1305–1314. [PubMed: 25529582]
- Wu J et al. (2016) Insertional Mutagenesis Identifies a STAT3/Arid1b/beta-catenin Pathway Driving Neurofibroma Initiation. *Cell Rep* 14:1979–1990. [PubMed: 26904939]
- Xiong Y, Li W, Shang C, Chen RM, Han P, Yang J, Stankunas K, Wu B, Pan M, Zhou B, Longaker MT, Chang CP (2013) Brg1 governs a positive feedback circuit in the hair follicle for tissue regeneration and repair. *Dev Cell* 25:169–181. [PubMed: 23602386]
- Yabe I, Soma H, Takei A, Fujik N, Sasaki H (2004) No association between FMR1 premutations and multiple system atrophy. *J Neurol* 251:1411–1412. [PubMed: 15592742]
- Yan Z, Wang Z, Sharova L, Sharov AA, Ling C, Piao Y, Aiba K, Matoba R, Wang W, Ko MS (2008) BAF250B-associated SWI/SNF chromatin-remodeling complex is required to maintain undifferentiated mouse embryonic stem cells. *Stem Cells* 26:1155–1165. [PubMed: 18323406]
- Yu Y, Yao R, Wang L, Fan Y, Huang X, Hirschhorn J, Dauber A, Shen Y (2015) De novo mutations in ARID1B associated with both syndromic and non-syndromic short stature. *BMC Genomics* 16:701. [PubMed: 26376624]

Highlights

- *Arid1b* haploinsufficiency leads to autistic behavior and intellectual dysfunction.
- *Arid1b* haploinsufficiency causes E/I imbalance due to abnormal GABA interneurons.
- Altered epigenetic modifications are associated with *Arid1b* haploinsufficiency.
- GABA PAM rescues abnormal behaviors induced by *Arid1b* haploinsufficiency.
- Recombinant growth hormone increases body size in *Arid1b* haploinsufficient mice.




Figure 1. Graphical model of the neuronal effects of *Arid1b* haploinsufficiency.

Arid1b heterozygous mice exhibit wider inhibitory synaptic clefts and narrower postsynaptic density (PSD). The mutant mice also show lower levels of transcription-activating histone post-translational modifications at specific GABAergic neuron-associated promoters. The latter leads to decreased phosphorylation of Ser 5 within the CTD of RNA polymerase II at these DNA loci, which is necessary for gene transcription. These changes in gene expression contribute to the functional, anatomical and behavioral abnormalities observed in *Arid1b* mutant mice.

Table 1.Selected genes with altered expression in *Arid1b* heterozygous mice

GENE	FUNCTION/DESCRIPTION	ASD ASSOCIATION*
<i>ARID1B</i>	Chromatin remodeling subunit	High confidence (syndromic)
<i>GRIN2B</i>	NMDA receptor subunit	High confidence
<i>ZBTB20</i>	Transcription factor	Suggestive evidence (syndromic)
<i>PRICKLE1</i>	Nuclear receptor	Suggestive evidence
<i>PRICKLE2</i>	Nuclear receptor	Suggestive evidence
<i>RBFOX1</i>	Alternative splicing regulator	Suggestive evidence
<i>HOMER1</i>	Postsynaptic density scaffolding	Minimal evidence
<i>LAMA1</i>	Laminin alpha 1 subunit	Minimal evidence
<i>MKL2</i>	Transcriptional coactivator	Minimal evidence
<i>NBEA</i>	A-kinase anchor protein	Minimal evidence
<i>NTNG1</i>	Neurite outgrowth-promoting protein	Minimal evidence
<i>SOX5</i>	Transcription factor	Minimal evidence
<i>SSPO</i>	Neuronal aggregation modulator	Minimal evidence
<i>EGR2</i>	Transcription factor	Hypothesized
<i>EPHA6</i>	Receptor tyrosine kinase	Hypothesized
<i>ITGA4</i>	Integrin subunit	Hypothesized
<i>ROBO1</i>	Membrane protein involved in axon guidance and cell migration	Hypothesized

* Based on Simons Foundation Autism Research Initiative (SFARI) numerical gene scoring: 1 = High confidence; 2 = Strong candidate; 3 = Suggestive evidence; 4 = Minimal evidence; 5 = Hypothesized; 6 = Not supported.

Table 2.

Summary of behavioral findings from three studies utilizing *Arid1b* heterozygous mice

HUMAN BEHAVIORAL CORRELATE	BEHAVIORAL ASSAY	CELEN ET AL., 2017	JUNG ET AL., 2017	SHIBUTANI ET AL., 2017
ANXIETY	Elevated Plus Maze	Heightened Anxiety	Heightened Anxiety	Heightened Anxiety
ANXIETY	Open Field	Heightened Anxiety	Heightened Anxiety	Unclear
ANXIETY	Light-Dark Box	Heightened Anxiety	n/a	No Change
DEPRESSION	Forced Swim	n/a	Increased Depression	Increased Activity
DEPRESSION	Tail Suspension	n/a	Increased Depression	n/a
SOCIAL INTERACTION	Three-Chamber Test for Sociability	n/a	Decreased Social Interaction	No Change
SOCIAL INTERACTION	Three-Chamber Test for Social Novelty Preference	n/a	Decreased Social Interaction	No Change
SOCIAL INTERACTION	Home-Cage Social Interaction	n/a	n/a	Decreased Social Interaction
SOCIAL INTERACTION	Open Field Social Interaction	Decreased Social Interaction	Decreased Social Interaction	No Change
COMMUNICATION	Ultrasonic Vocalizations	Altered Communication	n/a	n/a
REPETITIVE BEHAVIOR	Grooming	Increased Repetitive Behavior	Increased Repetitive Behavior	No Change
BEHAVIORAL INFLEXIBILITY	Barnes Maze	n/a	n/a	Decreased Behavioral Flexibility
INTELLECTUAL DISABILITY	Morris Water Maze	No Change	Impaired Spatial Memory	n/a
INTELLECTUAL DISABILITY	Novel Object Recognition	n/a	Impaired Recognition Memory	n/a
INTELLECTUAL DISABILITY	T-Maze	n/a	Impaired Learning	No Change
INTELLECTUAL DISABILITY	Barnes Maze	n/a	n/a	No Change
INTELLECTUAL DISABILITY/FEAR LEARNING	Fear Conditioning	No Change	n/a	Increased Long-Term Fear Memory and Fear Generalization
PAIN RESPONSE	Response to Foot Shock	No Change	n/a	Heightened Response to Stimulus